Our use of tech across every part of our company is revolutionising the way we understand, prevent and treat disease - helping us reimagine what’s possible for patients. Speaking on the TD Cowen Insights podcast, Shobie Ramakrishnan, Chief Digital and Technology Officer at GSK, discusses the power of science, tech and talent in tackling the most complex challenges, better and faster. 🔗 Listen here: https://gsk.to/3YVQaDU
關於我們
We are uniting science, technology and talent to get ahead of disease together. Our community guidelines: https://gsk.to/socialmedia
- 網站
-
http://www.gsk.com
外部葛兰素史克公司連結
- 產業
- 製藥製造
- 公司規模
- 10,001+ 名員工
- 總部
- LondonEngland
- 類型
- 上市公司
- 專長
- Pharmaceutical products和Vaccines
地點
葛兰素史克公司員工
動態消息
-
“Half of the world doesn’t have access to the basic healthcare it needs, and 2 billion people in the world can’t access the medicines that they need….I think the Pharma industry has to play its part in that. But we are not alone in it.” Our CEO, Emma Walmsley, joined other industry leaders at the FT Live Global Pharma and Biotech Summit today. In conversation with Drew Armstrong, Executive Editor of Endpoints, Emma discussed wide-ranging topics from building trust in pharma, to the importance of prevention and the transformative potential of AI in healthcare.
-
-
On Wednesday, our CEO, Emma Walmsley, will be speaking to Endpoints Executive Editor, Drew Armstrong at the FT Live Global Pharma and Biotech Summit, about crucial topics like the importance of prevention and the role of AI in healthcare. Want to join us? Register via the link below to watch her live: 📆 Date Weds 6 November ⏰ Time 10:20 GMT 📌 https://bit.ly/3YnqTm4 #FTPharma
-
-
The fight against malaria has made significant progress over the past 60 years, but what's next on the path towards elimination? The “Zero Malaria Experience”, created by our partner Malaria No More UK, takes us on a journey through the past, present, and future of malaria elimination and uses interactive technology to showcase data from Imperial College London’s world-leading scientists. Watch as Malaria No More ambassador David Beckham and a global alliance of malaria scientists, campaigners and global health experts explore the impact of tools like bed nets, malaria vaccines and treatments on communities in malaria-endemic countries. By increasing the coverage of existing tools and introducing new ones, such as next-generation vaccines, 13.2m lives could be saved between 2025 and 2040 with 10m of the lives saved children under five in sub-Saharan Africa. The future of malaria elimination is in our hands, and together, we can help #ChangeTheTrajectory and move closer to a malaria-free world. #ZeroMalaria #EndMalaria #GlobalHealth
-
“By combining organoid models of tumour tissue with AI, we are aiming to significantly increase our ability to predict whether or not a patient’s cancer will relapse and what is likely to be the best treatment option for that individual patient” - Professor Tony Ng from King’s College London, who is also head of oncology translational research at GSK. In the first trial of its kind, Ng and his team are growing millions of miniature living replicas of the tumours of dozens of NHS patients who have undergone surgery for non-small cell lung cancer, the most common form of the disease. Find out how tech like these ‘organoids’ paired with AI could transform lung cancer care 👇 (paywall) 🔗 https://gsk.to/3C98L6I
-
-
Today, we’re thrilled to be one of the first companies to adopt #ScienceBasedTargets #ForNature, starting with freshwater. Human health relies on healthy natural ecosystems and protecting nature helps build business resilience. That’s why we’ve set ambitious goals for nature. As a company with science at its core, we recognise the importance of a measurable and science-based approach. We’ve worked with Science Based Targets Network (SBTN) to adopt a freshwater target for our direct operations, with an initial focus on the Upper Godavari basin in India. To deliver this, we are reducing freshwater use at our manufacturing site in Nashik, enhancing water replenishment through nature restoration, as well as driving collective action with local stakeholders to address shared water challenges. Find out more: https://gsk.to/3C67qxo #SBTN #ScienceBasedTargets #ForNature #NaturePositive #COP16Colombia
-
-
News for #Investors and #Media Watch our CEO Emma Walmsley as she shares our Q3 results. We are on track to deliver 2024 outlooks with further good progress made in R&D. For more, visit https://gsk.com $GSK #Q3Results
News for #Investors and #Media I’m pleased to announce another quarter of sales and core operating profit growth for GSK. Strong performance in Specialty Medicines helped to offset lower Vaccines sales and reflected successful new product launches in Oncology and HIV, as well as the resilience we have now built into GSK’s portfolio and performance. It’s an exciting time for GSK. Our pipeline continues to strengthen with 11 positive phase III trials reported so far this year and we’re currently planning launches for 5 major new product approval opportunities next year. We’re well on track to deliver our performance commitments in 2024 and increasingly confident in our long-term outlooks – for growth and health impact at scale. When we grow, we’re helping more people with our innovative vaccines and medicines. And beyond the numbers, I see the positive impact we’re continuing to have on patients’ lives – tackling the toughest challenges in our industry to protect people and their loved ones. This is what getting ahead of disease together is all about.
-
News for #Investors and #Media This morning we announced our Q3 2024 performance – we are on track to deliver 2024 outlooks with further good progress made in R&D. Swipe to see our key highlights. For more insights, visit us at https://www.gsk.com. $GSK
-
#Investors and #Media Please read our cautionary statement regarding forward-looking statements and the definitions and reconciliations for non-IFRS measures for our Q3 2024 results. CER% represents constant exchange rates. £% or AER% represents actual exchange rates. $GSK For investors: https://gsk.to/4hoogb4
-
#News for #investors and #media: Today we announced an agreement to acquire an investigational medicine to potentially address continued unmet need in autoimmune diseases. https://www.gsk.com/en-gb/
-